TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Neuland Laboratories Ltd.

NEULANDLAB on NSE · 19 Nov 2026

NIFTY 500

21,102.00 ▼ -1.65 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Guidance tracker

What NEULANDLAB guided, and what came next

FiledWhat the filing saysNext results: profit YoYRevenueMove on the day
06 Nov 2026Neuland Laboratories filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 3, 2026, for the quarter and half year ended September 30, 2026. Total income for Q2 FY27 was Rs.457.2 crores versus Rs.516.1 crores a year earlier; H1 FY27 total income was Rs.1,107.2 crores versus Rs.816.7... NSE copy No results filed since
03 Nov 2026Neuland Laboratories filed its investor/analyst presentation on Q2FY27 and H1FY27 results for the quarter and half year ended September 30, 2026. Standalone total income for Q2FY27 was Rs. 457.2 crore, down 11.4% YoY; EBITDA was Rs. 104.6 crore (EBITDA margin 22.9%, down 754 bps YoY); PAT was Rs. 51.1 crore, down... NSE copy No results filed since
10 Aug 2026Neuland Laboratories filed the transcript of its Q1 FY27 earnings call held on August 5, 2026 for the quarter ended June 30, 2026, and said it has been uploaded to its website. Management said total income was INR650.1 crores versus INR300.6 crores a year earlier (growth of 16.3%), EBITDA was INR231.1 crores... NSE copy -46.7 %-12.6 %+0.8 %
16 May 2026Neuland Laboratories filed the transcript of its Q4 & FY26 earnings conference call held on May 12, 2026, uploaded to its website. Management reported Q4FY26 total income of INR788.7 crores, up 134.9% from INR335.8 crores, with gross margin of 62.1%, EBITDA of INR319.4 crores (40.5% margin) and profit after tax of... NSE copy +962.4 %+119.2 %+8.0 %
12 May 2026Neuland Laboratories filed its investor/analyst presentation on Q4FY26 and FY26 financial results (quarter and year ended March 31, 2026). Q4FY26 total income was Rs. 788.7 crore (134.9% YoY); EBITDA Rs. 319.4 crore (448.6% YoY) with EBITDA margin of 40.5%; PAT Rs. 212.5 crore (666.3% YoY). Net debt was Rs. (156.8)... NSE copy +962.4 %+119.2 %+8.0 %
12 May 2026Board approved audited standalone and consolidated (Ind AS) financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, for FY 2025-26, payable after approval at the 42nd... NSE copy +962.4 %+119.2 %+8.0 %
13 Feb 2026Neuland Laboratories filed the transcript of its Q3FY26 and 9MFY26 earnings conference call held on February 9, 2026. Abhijit Majumdar (CFO) said Q3FY26 total income was INR447.8 crores, up 11.4% YoY from INR401.9 crores, with gross margin at 52.1% versus 53.2% in Q3FY25 and EBITDA of INR85 crores at a 19% margin,... NSE copy ---3.0 %
12 Nov 2025Neuland Laboratories filed the transcript of its Q2 & H1 FY26 earnings conference call held on November 7, 2025, under Regulation 30 of the SEBI LODR Regulations. Management said Q2 FY26 total income was Rs. 516 crores odd, up 63.7% from Rs. 315 crores in the same period last year, with EBITDA of Rs. 156.9 crores... NSE copy -60.1 %+10.5 %-2.8 %
04 Aug 2025Neuland Laboratories filed the transcript of its Q1FY26 earnings conference call held on July 31, 2025 for the quarter ended June 30, 2025. Management reported total income of Rs. 300.6 crores, down 32.4% year-on-year from Rs. 444 crores, with EBITDA of Rs. 42.1 crores (14.4% margin) and profit after tax of Rs.... NSE copy +194.9 %+65.4 %+1.5 %
31 Jul 2025Neuland Laboratories filed its investor/analyst presentation on Q1FY26 (quarter ended June 30, 2025) results under Regulation 30. Q1FY26 total income was Rs. 300.6 crore (down 32.4% YoY); EBITDA was Rs. 42.1 crore (down 67.2% YoY), with EBITDA margin at 14%; PAT was Rs. 13.7 crore (down 86.1% YoY, Q1FY25 included... NSE copy +194.9 %+65.4 %+1.5 %
19 May 2025Neuland Laboratories filed the transcript of its Q4 and FY25 earnings call held on May 15, 2025. Management (Abhijit Majumdar, CFO) reported Q4 FY25 total income of INR335.8 crores, down 14% year-on-year from INR390.4 crores, EBITDA of INR58.2 crores (17.3% margin) and profit after tax of INR27.7 crores versus... NSE copy -85.8 %-33.4 %-2.0 %
15 May 2025Neuland Laboratories filed its Q4FY25 and FY25 investor/analyst presentation under Regulation 30 of the SEBI LODR Regulations, dated May 15, 2025. Q4FY25 total income was Rs. 335.8 crore (down 14.0% YoY); EBITDA was Rs. 58.2 crore (down 48.1% YoY) with EBITDA margin at 17.3% (down 1140 bps YoY); PAT was Rs. 27.7... NSE copy -85.8 %-33.4 %-2.0 %
14 Feb 2025Neuland Laboratories filed the transcript of its Q3 and 9MFY25 earnings call held on February 11, 2025, under Regulation 30 of the SEBI LODR Regulations. Management said Q3 total income was Rs. 401.9 crores, up 1.8% year-on-year, and Q3 EBITDA excluding exceptional items was Rs. 90.3 crores (margin 22.5%) versus... NSE copy -85.8 %-33.4 %-2.0 %
10 Feb 2025Neuland Laboratories filed its investor/analyst presentation on Q3FY25 and 9MFY25 results (quarter and nine months ended December 31, 2024). Q3FY25 total income was Rs. 401.9 crore (+1.8% YoY); EBITDA was Rs. 90.3 crore (down 26.4% YoY) with EBITDA margin at 22.5% (down 860 bps YoY). Q3FY25 PAT was Rs. 101.4 crore... NSE copy -85.8 %-33.4 %-2.0 %

Filings tagged as guidance, newest first (14 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.

Governance

Management, auditors, ratings and legal matters

FiledKindWhat the filing says
25 Aug 2026Credit ratingNeuland Laboratories intimated under Regulation 30 of SEBI Listing Regulations that Crisil Ratings has reaffirmed the Company's credit ratings. Long-term rating: CRISIL A+/Positive, reaffirmed with outlook revised to 'Positive'. Short-term rating: CRISIL A1, reaffirmed. NSE copy
05 Aug 2026Legal or regulatoryNeuland Laboratories' board, at its meeting on August 5, 2026, approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from the statutory auditors enclosed (the filing does not state the results figures). The board approved execution of an... NSE copy
13 Jul 2026Credit ratingNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated July 13, 2026. India Ratings and Research has affirmed the Company's credit rating. Bank loan facilities are rated IND A+/Positive/IND A1 with rating action "Affirmed". NSE copy
12 May 2026Management changeBoard approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, payable after shareholder approval at the 42nd AGM.... NSE copy
12 May 2026Management changeBoard approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10; record date July 24, 2026; 42nd AGM on August 4,... NSE copy
12 May 2026Management changeBoard approved audited standalone and consolidated (Ind AS) financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, for FY 2025-26, payable after approval at the 42nd... NSE copy
12 May 2026Management changeBoard approved audited standalone and consolidated Ind AS results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, payable on or after five days from declaration at the 42nd AGM;... NSE copy
31 Jul 2025Management changeNeuland Laboratories reported standalone unaudited results for the quarter ended June 30, 2025: revenue from operations of Rs 29,275.27 lakhs, total income of Rs 30,060.86 lakhs, and profit after tax of Rs 1,370.76 lakhs (compared with Rs 9,835.29 lakhs for the quarter ended June 30, 2024 on a total income of Rs... NSE copy
21 Jun 2025Credit ratingNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated June 21, 2025. CRISIL Ratings has reaffirmed the company's long-term rating at CRISIL A+/Stable. CRISIL Ratings has also reaffirmed the company's short-term rating at CRISIL A1. NSE copy
15 May 2025Legal or regulatory, Management changeBoard of Neuland Laboratories approved audited standalone and consolidated Ind AS results for the year ended March 31, 2025, with unmodified auditor opinion from MSKA & Associates. Board recommended a final dividend of Rs. 12 per equity share (120%) on face value Rs. 10 for FY 2024-25, payable on or after five days... NSE copy
15 May 2025Legal or regulatory, Management changeNeuland Laboratories' board approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2025, with unmodified auditor opinion from MSKA & Associates. Board recommended a final dividend of Rs. 12 per equity share (120%) on face value Rs. 10 for FY 2024-25, payable after... NSE copy
10 Mar 2025Credit ratingNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated March 10, 2025. India Ratings and Research has affirmed the Company's long-term rating at IND A+/Positive. Fund-based limits are affirmed at IND A+/Positive / IND A1, and non-fund-based limits at IND A1. NSE copy

Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (12 in all). A list of what was filed, not a judgement of the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in